Cholesterol metabolic reprogramming drives the onset of DLBCL and represents a promising therapeutic target
胆固醇代谢重编程是弥漫性大B细胞淋巴瘤（DLBCL）发病的主要驱动因素，并代表了一种有前景的治疗靶点。
期刊:Frontiers in Cell and Developmental Biology
影响因子:4.3
doi:10.3389/fcell.2025.1585521
Zhou, Lili; Cheng, Wei; Luo, Dan; Peng, Zhida; Mei, Jiaqi; Luo, Qingqing; Yu, Tiantian; Wang, Ya; Lei, Zhixiang; Huang, Chunhong; Yan, Nianlong; Luo, Daya; Yu, Li
